EFFECTS OF SAGYDI (SAD) ON ENDOGENOUS DYSLIPIDEMIA MODEL IN MICE

Abstract

Dyslipidemia is one of the popular issues in developed countries and an increasing trend in developing countries. It is a major risk factor for cardiovascular disease, hypertension and diabetes. Polyherbal formulations have been used to treat dyslipidemia for many years. This study was designed to evaluate the effects of SAGYDI (SAD) on endogenous dyslipidemia experimental animal model. In endogenous hyperlipidemia model, mice were previously treated by SAD and intraperitoneally injected by poloxamer - 407 to induce hyperlipidemia. They were divided into groups and intraperitoneally injected with a 2% P-407 solution, followed by oral administration of varying doses of SAD. The results showed that SAD at the daily doses of 0.72g dried extract/kg and 2.16g dried extract/kg significantly reduced the serum total cholesterol (TC) levels and serum non-HDL cholesterol levels by 13.56%, 14.49%, and 16.40%, 11.10%, respectively (p<0.05). So, SAD has demonstrated an impact on serum lipid modulations in endogenous dyslipidemia model in mice.